Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 5/20 | 0.44 |
| ▸ | PAK3 | O75914 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.43 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 9/20 | 0.40 |
| ▸ | CCND1 | P24385 | 8/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | CCND3 | P30281 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035355 | 0.89 | WEE1 (0.47) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035458 | 0.82 | WEE1 (0.45) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035265 | 0.78 | PAK3 (0.57) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035695 | 0.76 | WEE1 (0.42) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035417 | 0.74 | CDK4 (0.44) | PAK3PAK4LIMK1LIMK2PAK1 | |
| SCHEMBL15034833 | 0.74 | WEE1 (0.42) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035391 | 0.74 | WEE1 (0.45) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15034937 | 0.74 | PAK3 (0.43) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15041568 | 0.73 | CDK4 (0.46) | WEE1PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL15035529 | 0.73 | WEE1 (0.48) | WEE1PAK3PAK4LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | WEE1 545/4885PAK3 6/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.